This is the authors' abstract. We don't add key points for this paper.
With interest we read the Letter to the Editor of Wei and Sluis-Cremer about the role of human immunodeficiency virus type 1 (HIV-1) 3′-polypurine tract (3′PPT) mutations in dolutegravir (DTG) resistance (1). In particular, they report that the 3′PPT mutations identified by Wijting et al. (2) in a patient that failed on DTG monotherapy do not confer DTG resistance in a phenotypic drug resistance assay and conclude that genotypic analysis of the 3′PPT in HIV-1 resistance to integrase strand transfer inhibitors (INSTIs) is not warranted. However, we argue that it is too early for such a conclusion.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dekker et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: